8-K: Iterum Therapeutics Reports Q1 2024 Financials, NDA Resubmitted with FDA Action Expected in Early Q4

Iterum Therapeutics announced its first quarter 2024 financial results, highlighted by the resubmission of its New Drug Application (NDA) for oral sulopenem and an extended cash runway into 2025.

Summary

• Iterum Therapeutics reported a net loss of $7.1 million for the first quarter of 2024, compared to a net loss of $9.9 million for the same period in 2023.
• Research and development expenses decreased to $4.0 million from $6.4 million year-over-year, primarily due to the completion of the REASSURE trial enrollment.
• General and administrative expenses increased slightly to $2.2 million from $2.1 million year-over-year, due to higher legal and consultant fees.
• The company's cash, cash equivalents, and short-term investments totaled $18.2 million as of March 31, 2024.
• Iterum sold 3.0 million ordinary shares through an at-the-market offering, generating net proceeds of $7.2 million.
• The company has resubmitted its NDA for oral sulopenem, with FDA action expected in early Q4 2024.
• Iterum's cash runway is projected to extend into 2025, including through the potential FDA approval of oral sulopenem.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the NDA resubmission, extended cash runway, and improved net loss. However, the company is still operating at a loss and faces regulatory and financial risks.

Positives

• The resubmission of the NDA for oral sulopenem is a significant step towards potential FDA approval.
• The extended cash runway into 2025 provides financial stability for the company.
• The decrease in R&D expenses indicates the completion of the costly REASSURE trial.
• The net loss improved year-over-year, suggesting better cost management.
• The company successfully raised $7.2 million through an at-the-market offering.

Negatives

• The company continues to operate at a loss, with a net loss of $7.1 million for the quarter.
• General and administrative expenses increased slightly, primarily due to higher legal and consultant fees.
• The company is reliant on FDA approval for oral sulopenem to achieve commercial success.
• The company has a shareholders' deficit of $6.15 million.

Risks

• The FDA may not approve the resubmitted NDA for oral sulopenem.
• The company's cash resources may not be sufficient to fund operations beyond 2025.
• There are risks associated with the commercialization of oral sulopenem, if approved.
• The company is subject to risks related to clinical trials, regulatory approvals, and market competition.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital or achieve profitability.

Future Outlook

Iterum expects its current cash resources to fund operations into 2025, including through the potential FDA approval of oral sulopenem in early Q4 2024. The company is also exploring strategic alternatives for sulopenem.

Management Comments

• Corey Fishman, Iterum's Chief Executive Officer, stated that the company is pleased to have resubmitted the NDA for oral sulopenem.
• Corey Fishman believes that the strong results from the REASSURE trial address the FDA's recommendations for additional data to support approval of oral sulopenem.

Industry Context

The potential approval of oral sulopenem would be significant as it would be the first oral penem approved in the U.S. and only the second antibiotic approved for uUTIs in the past 25 years, addressing a critical need for new treatments against multi-drug resistant pathogens.

Comparison to Industry Standards

• Iterum's focus on developing novel antibiotics aligns with the broader industry trend of addressing antimicrobial resistance.
• The company's progress with sulopenem is comparable to other clinical-stage pharmaceutical companies developing new antibiotics, such as Nabriva Therapeutics and Achaogen (now defunct).
• The successful completion of the REASSURE trial and NDA resubmission are key milestones similar to those achieved by other companies in the antibiotic development space.
• The company's cash runway into 2025 is a positive sign, but it will need to continue to raise capital or achieve profitability to sustain operations, similar to other companies in the sector.

Stakeholder Impact

• Shareholders may benefit from potential FDA approval of oral sulopenem and the company's extended cash runway.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Patients may benefit from the availability of a new treatment option for uUTIs if oral sulopenem is approved.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The FDA will review the resubmitted NDA for oral sulopenem.
• The company expects FDA action on the NDA in early Q4 2024.
• Iterum will continue to advance its strategic process to sell, license, or otherwise dispose of its rights to sulopenem.
• The company will continue to manage its cash resources to fund operations into 2025.

Key Dates

Keywords

Iterum Therapeutics, sulopenem, NDA, FDA, uUTI, antibiotics, REASSURE trial, financial results, cash runway, pharmaceutical